In the course of our screening for a new anti-tumor substance, the bisabolane sesquiterpenoid endoperoxide, 3,6-epidioxy-1,10-bisaboladiene (EDBD), was isolated from the edible wild-plant, Cacalia delphiniifolia. EDBD showed cytotoxicity toward human chronic myelogenous leukemia K562 and human prostate carcinoma LNCaP cell lines with IC 50 values of 9.1 M and 23.4 M, respectively. DNA fragmentation and condensation of chromatin, the hallmarks of apoptosis, appeared in K562 cells after an 18-h treatment with EDBD. -Curcumene, a bisabolane sesquiterpene that lacks the endoperoxide moiety of EDBD, also showed cytotoxicity toward both K562 and LNCaP cell lines at over a 10-times higher dose than that of EDBD. The results indicate the importance of the endoperoxide structure within EDBD to its anti-tumor activity in vitro.
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The mechanism for eukaryotic cell-cycle regulation is closely linked to cellular tumorigenesis. Low-molecularweight compounds that affect the cell cycle, especially those which induce G1 arrest, could be good candidates for developing anti-tumor drugs. The yeast, Saccharomyces cerevisiae, has cellular processes that are highly conserved to human cells. In addition, the technical advantages of this organism such as its simple growth conditions, rapid cell division and the availability of genetic tools have expanded the application of yeast as a screening tool for drug discovery. [1] [2] [3] We have previously screened cell-cycle modulators on a culture broth of various microbes, including Actinomycetes and fungi, by using S. cerevisiae yeast as the target, and identified such compounds possessing anti-tumor activity as mycophenolic acid, borrelidin and fredericamycin. [4] [5] [6] We describe in this paper the identification of 3,6-epidioxy-1,10-bisaboladiene (EDBD) from the edible plant, Cacalia delphiniifolia, as a novel biological substance that induced apoptosis.
In the course of our screening, we found that the MeOH extract of C. delphiniifolia induced G1 delay in S. cerevisiae cells. C. delphiniifolia (Shidoke/Momijigasa) is a wild-grown edible plant endemic to the northern part of Japan. Fresh C. delphiniifolia (651.7 g, grown in Iwate prefecture) was dried at room temperature (57.28 g), and the active component was extracted with MeOH (13.65 g). The extract was diluted with an excess of water and extracted twice with EtOAc. After evaporating EtOAc (3.06 g), the organic layer was chromatographed in a silica-gel column (4 cm dia. Â 34 cm) with hexane:EtOAc = 10:1 and 5:1 used as the eluent (1.15 g). Finally, the active compound was purified by reverse-phase HPLC in a Capcell Pak column (20 mm dia. Â 250 mm; Shiseido Co., Ltd., Japan), eluting with 75% MeOH at 10 ml/min, monitoring by UV (204 nm), and extracting with hexane (25.3 mg).
The active compound was obtained as yellowish oil and was dissolved in CHCl 3 and MeOH. The Rf value by silica gel TLC (Wako, Silicagel 70F 254 , 0.25 mm), using a solvent system of hexane-EtOAc (5:1) was 0.53; ½ Complete NMR assignment was performed by using 2D NMR spectral data, including HMBC and NOESY. In the NOESY spectrum, each cross peak was observed between CH 3 -14 at 0.986 ppm and H-5a protons in the major diastereomer, CH 3 -14 at 0.994 ppm and H-1 protons in the minor diastereomer. HR-ESI-MS m=z (M + H) þ : calcd. for C 15 H 25 O 2 , 237.1855; found, 237.1850 (Jeol JMS-700). All examined physico-chemical properties and NMR data were identical with the data for EDBD (Fig. 1A) in the reference, except some NMR assignments. 7) EDBD has previously been isolated from Melicope borbonica, 7) Senecio paludaffinis, 8) Ligularia speciosa, 9) Chamaemelum fuscatum, 10) Artemisia xanthochroa, 11) and Santolina rosmarinifolia subsp. Canescens.
12) It has been reported that this compound possessed antifungal and antimalarial activities. 7, 12, 13) Our result is the first case showing the presence of EDBD in C. delphoniifolia and its anti-tumor activity in vitro.
To assess the anti-tumor activity of EDBD in vitro, we added the compound to a cell culture of human chronic myelogenous leukemia K562 (ATCC CCL-243) and human prostate carcinoma LNCaP (ATCC CRL-1740) cell lines, and monitored their viability after incubating for 4 d at 37
C by using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The percentage of viable cells was calculated as the ratio of the A 570 values for EDBD-and vehicle (5% methanol)-treated cells. EDBD showed cytotoxicity toward both K562 and LNCaP cells in a dose-dependent manner; the IC 50 values of the compound for each cell line were 9.1 mM and 23.4 mM, respectively (Fig. 1C ). -Curcumene (1,3,5,10-bisabolatetraene) has a chemical structure closely resembling EDBD, but it lacks an endoperoxide moiety (Fig. 1B) . This compound is the constituent of a large number of plants and essential oils, and its anti-tumor activity has previously been reported, although the mechanism of action is obscure. 14) To compare the anti-tumor activity of EDBD andcurcumene in vitro, we purified -curcumene from the essential oil of ginger (Seikatsunoki Co., Tokyo, Japan) by using HPLC (Capcell Pak 10 mm dia. Â 250 mm column, 80% ethanol at 3 ml/min, UV (265 nm)) and hexane extraction. cytotoxicity toward both K562 and LNCaP cells, the IC 50 values for the compound were over 10-times higher than those for EDBD, i.e., 256.5 mM and 277.5 mM, respectively (Fig. 1C) . We also tested the cytotoxicity of bisabolene and bisabolol (Wako Pure Chemical Industries, Osaka, Japan), analogs of -curcumene, and found that these compounds showed cytotoxicity at similar concentrations to those of -curcumene:K562 (IC 50 ¼ 212:2 and 187.6 mM) and LNCaP (IC 50 ¼ 256:5 and 151.9 mM), Fig. 1C . 15) In order to understand the physiological role of EDBD and -curcumene, we observed the cellular and nuclear morphology of EDBD-and -curcumene-treated K562 cells (18 h with 10 mg/ml (42.2 mM) of EDBD and 75 mg/ml (371.3 mM) of -curcumene) under a fluorescent microscope, after staining with Hoechst 33342 (Dojindo Laboratories, Kumamoto, Japan). As shown in Fig. 2 , the nuclei of the EDBD-and -curcumene-treated cells had a more compact and brightly stained profile than nuclei of the vehicle-treated cells, and fragmentation of the nucleus was sometimes observed. This result suggested that EDBD and -curcumene induced apoptotic cell death. To confirm this possibility, DNA was prepared from EDBD-and -curcumene-treated K562 cells, and its size was monitored by 2% agarose gel electrophoresis. DNA fragmentation, a hallmark of apoptosis, was observed with DNA samples from the EDBD-treated cells (Fig. 3A, lanes 5 to 7) , while it was not apparent with the vehicle-treated cells (Fig. 3A, lane 2) . We also examined the effect of -curcumene on cellular DNA, and found that the compound also caused DNA fragmentation of the K562 cells (Fig. 3B) . The minimum concentrations of EDBD and -curcumene to induce DNA fragmentation were 6 mg/ml (25.3 mM, Fig. 3A , lane 5) and 70 mg/ml (346.5 mM, Fig. 3B, lane 4) , respectively, indicating that EDBD had over 10-times higher activity than -curcumene. This result shows good correlation with the IC 50 values and the concentration for nuclear morphological change of each compound. Cell cycle profiles obtained by using a fluorescent activated cell sorter (FACS) showed the subG1 population to have been increased by the treatments with EDBD and -curcumene in a dose-dependent manner (data not shown). Our results suggest the possibility that EDBD and -curcumene prevented tumor cell proliferation by inducing apoptosis, and that the endoperoxide structure greatly enhanced the activity. Alternatively, it is also possible that each compound bound to different target molecules, both of which play an important role in the apoptotic pathway. We are now exploring the molecular mechanism for the EDBD function in the more sensitive HL60 cell line and S. cerevisiae cells.
We isolated EDBD from C. delphiniifolia as an apoptosis-inducing substance toward K562 cells. Although this plant is a popular edible wild plant, these has been little study of its functional ingredients. Cacalol has already been isolated as an antioxidative compound from C. delphiniifolia, and EDBD is the first functional compound having anti-tumor activity in vitro derived from it. 16) Since the safety of this plant for human consumption has been known for many years, this might be a new type of dietary cancer-chemopreventive plant. 17, 18) 
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